Organovo Holdings Inc: Did We Learn Anything New From Earnings?

Find out the single most important variable to take away from this bioprinter's release.

Feb 10, 2014 at 9:15AM

You'd be hard-pressed to find a stock as richly valued by traditional metrics as Organovo Holdings (NYSEMKT:ONVO). The company has brought in a measly $264,000 in revenue over the past nine months, and increased its share count a whopping 60%. Despite this, it is valued at roughly $720 million.

The reason for the disparity is the excitement -- warranted or not -- surrounding the company's technology. Organovo is a leading 3-D bioprinter, and it will take its first real product to market by the end of the year.

Screen Shot

Source: Organovo

While some may get excited about the possibility of one day printing human organs, even-keeled investors would be wise to focus on what the company is actually working on right now: creating liver tissues for use by pharmaceutical companies. These 3-D tissues can be used to detect liver toxicities before drug companies entering FDA clinical trials, potentially saving billions of dollars.

The company got a big boost in January when it announced that its liver cells had passed functional validation tests well ahead of schedule. In essence, this meant that the company's bio-printed liver tissue had responded to known toxins in a manner that mimicked how native tissue does.

Just as important, Organovo delivered its first batch of liver tissue to a key opinion leader -- in this case, a top research scientist -- well ahead of schedule. With the accelerated timeline, it also pushed up its product launch to some time before December 2014 -- though specific details weren't given.

So did we learn anything from the company's earnings?
In short: not much.

Because Organovo won't be generating any significant revenue until the end of the year, there's not much to reveal. As in past quarters, much of the important news was just a recap of events we already knew about: partnerships with the NIH to produce eye tissue, collaborative agreements to research and print skin tissues, and initial data on 3-D bioprinted breast cancer tissue.

In fact, the only important thing of note to individual investors was a review of the company's financial position. As I said in the outset, Organovo has increased its share count by 60% over the past year -- due in no small part to its lack of significant revenue. At the end of 2013, the company had $50 million in cash on hand. The hope, for those invested in the company, is that this money can bridge the gap between now and when real revenue starts to come in at the end of the year. Though the company increased its head-count by 35% to 39 full-time employees, and has doubled its R&D expenditures, it should -- based on historical cash burn -- be able to make it until 2015 without more rounds of public financing.

Of course, that's no guarantee, and any additional rounds of funding wouldn't necessarily be reason to panic, as the company may simply be raising funds to expand capabilities with exciting new technologies. No matter the outcome, investors need to keep their eyes on two things moving forward: the launch of 3-D liver tissues later this year, and the overall cash position of the company.

Benefit from 3-D printing with more solid, profitable players
For the first time since the early days of this country, we're in a position to dominate the global manufacturing landscape thanks to a single, revolutionary technology: 3D printing. Although this sounds like something out of a science fiction novel, the success of 3D printing is already a foregone conclusion to many manufacturers around the world.

Although Organovo is exciting, its still very speculative.  The trick now is to identify the companies -- and thereby the stocks -- that will prevail in the battle for market share. To see the three companies that are currently positioned to do so, simply download our invaluable free report on the topic by clicking here now.

Brian Stoffel owns shares of Organovo Holdings The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers